Short-term Outcomes of Ranibizumab Biosimilar CKD-701 Treatment in Macular Edema Secondary to Retinal Vein Occlusion
10.3341/jkos.2025.66.1.27
- Author:
Daeun SHIN
1
;
Yeji KIM
;
Jae Hui KIM
Author Information
1. Kim’s Eye Hospital, Seoul, Korea
- Publication Type:Original Article
- From:Journal of the Korean Ophthalmological Society
2025;66(1):27-35
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose:To evaluate the short-term outcomes of intravitreal injection therapy using the ranibizumab biosimilar CKD-701 in macular edema due to retinal vein occlusion.
Methods:We conducted a retrospective analysis of medical records from patients diagnosed with macular edema secondary to retinal vein occlusion who received intravitreal injections of CKD-701. The best-corrected visual acuity (BCVA) and central retinal thickness (CRT) before and after a single injection were compared. Additionally, differences in these indicators were assessed between central and branch retinal vein occlusion (CRVO/BRVO).
Results:The study included 22 subjects, with 17 cases of BRVO and 5 cases of CRVO. The efficacy was evaluated at 6.0 ± 2.2 weeks after injection. CRT decreased significantly from 534.8 ± 224.9 µm before injection to 367.8 ± 162.7 µm after injection (p < 0.001). The logarithm of the minimum angle of resolution BCVA improved significantly from 0.58 ± 0.41 to 0.48 ± 0.37 after injection (p = 0.002). The CRVO group showed a greater reduction in CRT compared to the BRVO group (p = 0.006).
Conclusions:A single injection of CKD-701 significantly improved both functional and anatomical outcomes in patients with macular edema secondary to retinal vein occlusion. Additional long-term studies are needed.
